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Abstract: Nitric oxide (NO) is an important regulator of vascular tone, and is also an 
  antithrombotic, anti-inflammatory, antiproliferative, and antiatherogenic factor. Endothelial 
function is altered in patients with coronary artery disease, stroke, and peripheral artery disease, 
and endothelial dysfunction correlates with the risk factor profile for a patient. Hypertension and 
type 2 diabetes are risk factors for vascular disease, and are both pathologies   characterized by loss 
of NO activity. Indeed, endothelial dysfunction is usually present in diabetic and/or hypertensive 
patients. Tetrahydrobiopterin is an essential cofactor for the NO synthase enzyme, and insufficiency 
of this cofactor leads to uncoupling of the enzyme, release of superoxide, endothelial dysfunction, 
progression of hypertension, and finally, proatherogenic effects.   Tetrahydrobiopterin is also an 
important mediator of NO synthase regulation in type 2 diabetes and hypertension, and may be 
a rational therapeutic target to restore endothelial function and prevent vascular disease in these 
patients. The aim of this paper is to review the rationale for therapeutic strategies directed to 
biopterins as a target for vascular disease in type 2 diabetic hypertensive patients.
Keywords: tetrahydrobiopterin, endothelial dysfunction, diabetes, hypertension, oxidative 
stress, nitric oxide, eNOS synthase uncoupling
Introduction
The endothelium maintains the integrity of the vascular system via interaction between 
nitric oxide (NO) and vasoconstrictive factors.1 Endothelial dysfunction develops 
when the bioavailability of NO decreases, triggering a vasoconstrictive, proliferative, 
proinflammatory, and procoagulant condition that facilitates vascular damage.1,2
Both type 2 diabetes and hypertension increase oxidative stress and lead to 
  endothelial dysfunction.1 Endothelial dysfunction plays a key role in the   pathophysiology 
of atherogenesis and diabetes-associated vascular disease, and explains, at least in part, 
the enhanced progression of cardiovascular disease in type 2 diabetes.3
Despite being a radical, oxygen is sparingly reactive because its two unpaired 
electrons are situated in different molecular orbits. However, in endothelial cells, 
oxygen undergoes univalent reduction to form superoxide by means of enzymes such 
as nicotinamide adenine dinucleotide phosphate (NADH/NADPH) oxidase.4 Vascular 
NADH/NADPH oxidase is active during normal metabolism,5 and sustained activation 
of this enzyme occurs in response to several stimuli, including angiotensin II,   thrombin, 
platelet-derived growth factor, endothelin-1, tumor necrosis factor-alpha (TNFα), 
hypercholesterolemia, and hyperglycemia.6 Also, some vascular flow conditions may 
determine regulation of NADPH oxidase, whereby laminar shear stress downregulates Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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NADPH oxidase activity, whereas oscillatory shear stress 
induces a sustained increase in oxidase activity.4
Tetrahydrobiopterin
It was once believed that the only function of tetrahydrobiop-
terin (BH4) was as a cofactor for the activity of phenylalanine, 
tyrosine, and tryptophan hydroxylases during neurotransmitter 
synthesis. However, 20 years ago, when nitric oxide synthase 
(NOS) was characterized, BH4 was soon identified as one of 
its essential cofactors.7 Since this observation, BH4 has been 
implicated as a significant determinant of NO bioavailability 
and concomitant conduit/resistance vessel functions.
Each monomer of endothelial NOS (eNOS) has one 
BH4 binding site in the oxygenase domain and because the 
enzyme acts functionally as a dimer, two molecules of BH4 
are incorporated into each eNOS complex.8 In the active 
site, BH4 stabilizes the ferrous-dioxygen complex, and the 
cofactor also donates electrons to the oxygenase domain, and 
this is the initiating step of L-arginine oxidation.9,10 If BH4 
is reduced, electron transfer from eNOS becomes uncoupled 
from L-arginine oxidation, the ferrous-dioxygen complex 
dissociates, and the enzyme produces superoxide instead 
of NO.
When large amounts of reactive oxygen species (ROS) 
are present in the endothelial cell, electron transfer within the 
active site of eNOS becomes “uncoupled” from L-arginine 
oxidation. This process is known as eNOS uncoupling and 
under those conditions, electron flow through the enzyme 
results in reduction of molecular oxygen at the prosthetic 
heme site rather than formation of NO, and molecular 
  oxygen is reduced to form superoxide, leading to endothelial 
dysfunction.11
Several studies have shown that when BH4 is oxidized 
to dihydrobiopterin (BH2), the bioavailability of BH4 for 
eNOS is reduced. This is seen when BH4 reacts with super-
oxide or with peroxynitrite, which leads to eNOS uncoupling 
and finally, to endothelial dysfunction.11 In addition, BH2 
(which has no cofactor activity) may compete with BH4 
for the oxygenase domain in eNOS, leading to decreased 
eNOS activity.8
Tetrahydrobiopterin synthesis
Biosynthesis of BH4 can occur by one of three pathways, 
ie, from guanosine triphosphate cyclohydrolase I (GTP-CHI) 
via a de novo synthetic pathway, from sepiapterin via the 
salvage pathway, and via recycling pathways.12
Via the de novo pathway, BH4 synthesis is initiated by 
the action of GTP-CHI, which represents the rate-controlling 
enzyme and initiates GTP degradation to 7,8   dihydroneopterin 
triphosphate, which is converted to 6-  pyruvoyl-  tetrahydropterin 
by the 6-6-pyruvoyl synthase enzyme. Finally, the 6-pyruvoyl-
tetrahydropterin is reduced to BH4 by NADPH-dependent 
sepiapterin reductase (Figure 1).
Via the salvage pathway, sepiapterin is metabolized to 
7,8-BH2 and finally, to BH4 by two NADPH-dependent 
enzymes, ie, sepiapterin reductase and dehydrofolate 
reductase (Figure 1). However, sepiapterin is not a physi-
ologic metabolite in humans or animals.9
In the recycling pathway, BH4 is generated   differently, 
depending on the enzymes involved. When aromatic 
aminohydrolases are present, BH4 is regenerated from 
BH4α-carbinolamine in a two-step process, whereby 
pterin-4α carbinolamine dehydratase produces the   quinonoid 
BH2 intermediate, which is subsequently reduced by 
6,7-dihydropteridine reductase. When NOS is involved, BH4 
is transformed to a BH3.H+ radical, which is subsequently 
reduced in the next catalytic cycle by electron transfer from 
eNOS flavins9 (Figure 1).
Regulation of tetrahydrobiopterin
As mentioned in the previous section, the GTP-CH enzyme 
is critical for BH4 synthesis, and several studies have 
demonstrated that vascular agonists may increase BH4 
production through GTP-CH mRNA induction. Incubation 
of endothelial cells with phenylalanine increases mRNA 
levels for GTP-CH by 2.2-fold after 6 hours,13 and interest-
ingly, similar concentrations of phenylalanine increase BH4 
levels in bovine coronary endothelial cells by 16%.14 Insulin 
increases mRNA for GTP-CH, which enhances endothelial 
BH4 through the activation of the de novo pathway.15 Addi-
tion of 17β-estradiol to culture medium elevated both mRNA 
levels for CGT-CH and intracellular BH4 levels in brain 
microvascular endothelial cells.16 Inflammatory cytokines, 
such as interleukin (IL)-1β, interferon-γ or TNFα, increase 
BH4 synthesis, probably through the effect of increasing 
mRNA for GTP-CH.17 Finally, statins and cyclosporine can 
increase BH4 synthesis and GTP-CH mRNA in cultures of 
endothelial cells.14,18
Table 1 Factors that increase guanosine triphosphate cyclohydrolase I 
activity
Cytokines Transcriptional factors Inflammatory 
mediators
Interferon γ
Tumor necrosis 
factor α
Nuclear factor κB  
Signal transducer  
and activator  
of transcription 1/3
LipopolysaccharidesIntegrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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On the other hand, several studies have demonstrated that 
some vascular agonists may decrease BH4   production through 
GTP-CH mRNA downregulation. Johns et al found that 
  dexamethasone decreases the expression of GTP-CH mRNA 
and BH4 levels in endothelial cells.19   Similarly, inflamma-
tory cytokines, such as IL-4, IL-10, and transforming growth 
factor-beta, decrease BH4 synthesis, probably through 
GTP-CH mRNA downregulation.20
In addition to regulation of BH4 synthesis through these 
already described mRNA mechanisms, there are two other 
conditions where changes in BH4 bioavailability have been 
demonstrated. It has recently been reported that increasing 
concentrations of L-arginine raised intracellular levels of BH4 
production in cultured bovine coronary endothelial cells. This 
effect is specific for the L-isomer and is not affected by the use 
of arginase inhibitors.14 This in vitro observation was further 
supported by in vivo studies in which dietary   supplementation 
of L-arginine increased BH4 availability in coronary   endothelial 
cells from control and diabetic rats.21 In light of the reducing 
properties of BH4, the possibility that oxidative stress may 
affect BH4 availability arises. Indeed, the use of peroxynitrite 
in intact arteries demonstrated that oxidative stress is associated 
with BH4 reduction.22 Moreover, the hypothesis that BH4 acts 
as a reducing agent is further supported by the demonstration 
that vitamin C stabilizes BH4 in cultured endothelial human 
cells, through a mechanism not related to the interaction of 
vitamin C and superoxide anions.23
Interaction between 
tetrahydrobiopterin  
and nitric oxide synthase
NO is synthesized from L-arginine by NOS. Molecular 
  cloning has identified three distinct NOS isoforms,24 two of 
which are expressed constitutively in neurons and vascular 
endothelial cells, and are activated by increased intracellular 
calcium levels. The expression of the third isoform is induced 
in a calcium-independent fashion by several   agonists. All NOS 
isoforms catalyze the reaction of 1.5 mol NADPH + 1 mol 
L-arginine to 1 mol citrulline + 1 mol NO + 1.5 NADP+. 
This reaction is fully dependent on BH4. NOS contains a 
prosthetic heme group catalyzing the reductive activation of 
molecular oxygen which is required for L-arginine   oxidation, 
as well as tightly bound flavins shuttling NADPH-derived 
electrons to the heme (Figure 2).25 In this reaction, heme Fe3+ 
is reduced by flavin mononucleotide to heme Fe2+, which binds 
molecular oxygen to form an unstable dioxygen complex 
(heme-Fe-O-O) that, in the presence of BH4, is converted 
to heme-Fe3+-O-OH, then converted to heme-Fe5+=O, to par-
ticipate in the release of NO (Figure 2). BH4 in this reaction 
participates in the following events: BH4 binding to NOS 
GTP
BH4 synthesis
7-8 dihydroneopterin triphosphate
6 Pyruvoyletetrahydrobiopterin
BH4
Tetrahydrobiopterin
4α-carbinolamine
BH3.H+
NOS-Flavin NOS
PTPS
GTP-CH
Aromatic
SR
Sepiapterin
7-8 diHydrobiopterin
Sepiapterin
reductase
 
diHydrofolate
reductase
 
Quinoid-dihydrobiopterin
PCD
DHPR
Figure 1 Tetrahydrobioterin synthesis.
Abbreviation: BH4, tetrahydrobiopterin; GTP-CH, GTP cyclohydrolase; PTPS, pyruvoyl tetrahydrobiopterin synthase; SR, sepiapterin reductase; DHPR, dihydrofolate 
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stabilizes loose dimer conformation;26 BH4 binding to NOS 
enhances L-arginine binding to heme and inhibits superoxide 
release from the heme oxygenase domain of the enzyme.27
NO synthesis by eNOS can be affected by different stimuli, 
ie, signaling molecules (integrated into caveolae), phospho-
rylation (by Akt) at serine 177 residues in response to shear 
stress or hormones (such as estrogens or insulin) activating the 
enzyme, whereas phosphorylation at threonine 459 (by protein 
kinase C) decreases the activation of eNOS. Dephosphorylation 
of   threonine 459 in response to bradykinin activates eNOS.8
Deficient BH4 levels in several in vitro and in vivo 
animal models have correlated with low NO production in 
vascular   tissue.28 Recent studies suggest that disruption of 
the zinc-  thiolate complex at the dimer interface, close to the 
BH4   binding site, leads to loss in BH4 from the binding site, 
  enzymatic   uncoupling, and destabilization of eNOS dimers.29
The data suggest that eNOS uncoupling and increased 
nitrosylation of eNOS, decreased expression of GTP-CHI 
and sepiapterin reductase, and subsequent reduced BH4 
bioavailability, may be important contributors to endothelial 
dysfunction and its consequences.
NO produced by endothelial cells protects blood vessels 
from thrombosis, and has antiatherosclerotic activity. Enhanced 
NO bioactivity reduces atherosclerosis progression through 
multiple mechanisms (Table 2). All major risk factors for ath-
erosclerosis are associated with impairment of NO activity.15
Superoxide generation has been implicated in a variety of 
experimental and clinical vascular disease states, including 
diabetes, cigarette smoking, hypertension, chronic nitrate 
tolerance, and overt atherosclerosis, not only because of the 
increased production of ROS but also because of the reduced 
formation of the protective molecule NO.31
Tetrahydrobiopterin in disease
In the absence of enough BH4, instead of oxidizing L-  arginine, 
eNOS reduces molecular oxygen to superoxide, leading to 
endothelial dysfunction.32 When NO reacts with superoxide, 
it loses its vasodilatory, antiatherogenic, antithrombotic, anti-
inflammatory, and antiproliferative effects.33
e+
NADPH
NADP
FAD
FMN
Fe
CaM
BH4
Fe
CaM
e+
NADPH
NADP
FAD
FMN
O2
O2
NO
O2
O2-*
L-Arg L-Arg
Coupled NOS Uncoupled NOS
Figure 2 Interaction between tetrahydrobiopterin and nitric oxide synthesis.
Table 2 Antiatherosclerotic effects of nitric oxide
• Decreases endothelial permeability
• Inhibition of low-density lipoprotein oxidation
• Reduces influx of lipoproteins into the vascular wall
• Inhibition of proliferation of vascular smooth muscle cells
• Prevention of leukocyte adhesion to vascular endothelium
• Inhibition of leukocyte migration into the vascular wallIntegrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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BH4 prevents peroxynitrite-induced nitration of   proteins, 
and the prevention of nitration of tyrosine residues in cells 
stimulated by proinflammatory cytokines avoids the affec-
tation of proteins involved in energy production, fatty acid 
metabolism, apoptosis, and oxidative stress induced by 
peroxynitrite.34
Experimental evidence reveals that altered glucose 
metabolism results in low BH4 bioavailability, and also that 
BH4 levels are reduced in diabetic rats. Interestingly, dietary 
supplementation with BH4 in insulin-resistant rats prevents 
impaired endothelial-dependent vasodilatation.12
The main cause of impaired endothelium-dependent 
relaxation in insulin-resistant rats is abnormal metabolism 
of BH4. The mechanism seems to be an imbalance between 
NO and superoxide anion.32 NO regulates vascular tone 
and blood pressure, and a reduction in NO bioavailability 
increases vascular tone and raises blood pressure,4 so BH4 
may be involucrate in the maintenance of blood pressure 
and a decrease in its bioavailability may play a role in the 
pathways that lead to hypertension.12
Therapeutic considerations
BH4 as a therapeutic agent
Several in vivo studies in animals and in humans have shown 
the beneficial effect of BH4 on endothelial dysfunction and 
its vasoprotective properties. Therefore, enhancing BH4 
synthesis or bioavailability in endothelial cells may be a good 
strategy for the prevention and treatment of cardiovascular 
disease, especially in high-risk patients, such as hypertensive 
and diabetic subjects.34
When BH4 is administrated in healthy volunteers, the 
bioavailability of NO is increased. Several clinical trials have 
evaluated the use of BH4 for the management of endothelial 
dysfunction, and it has been shown that this cofactor increases 
acetylcholine-induced vasodilatation in coronary arteries in 
patients with coronary heart disease.35
The administration of BH4 improves forearm circulation in 
smokers, and diabetic or hypercholesterolemic patients, then, 
actions that lead to improve BH4 availability may be effective 
in restoring NO-mediated endothelial function and limiting 
vascular disease progression in several conditions, such as 
atherosclerosis, diabetes, and hypertension.36 Indeed,   infusion 
of BH4 improves the endothelial-dependent vasodilation 
response to acetylcholine but not the endothelium-independent 
vasodilation response to nitroprusside. In patients with type 2 
diabetes, the cofactor has no effect in control subjects.32
In healthy subjects, impairment of endothelial function 
induced by an oral glucose challenge was reversed by the 
active cofactor BH4, but not by an inactive stereoisomer.37 
In patients with type 2 diabetes, infusion of BH4 corrects 
endothelial dysfunction via an NO-dependent pathway.12
The administration of BH4 to spontaneously   hypertensive 
rats is associated with improvement of endothelial   function and 
prevention of hypertension and ventricular hypertrophy.12
Porkert et al found that oral administration of BH4 400 mg 
had a significant antihypertensive effect in poorly controlled 
hypertensive patients.38 They also found an improvement of 
endothelial function in this study, and the beneficial effect of 
BH4 was maintained during the eight-week study duration 
without tachyphylaxis. However, only patients receiving the 
BH4 dose of 400 mg or higher responded to the biopterin, 
whereas patients at a daily dose of 200 mg did not achieve a 
significant reduction in blood pressure.
Settergren et al showed that the administration of L-  arginine 
and BH4 improves endothelial function and reduces endothelial 
dysfunction induced by ischemia-reperfusion in type 2 diabetic 
patients with coronary artery disease.39 However, both agents 
were given in combination, so it was not possible to evaluate 
if administration of each agent alone would   demonstrate the 
same results or if the combination is   necessary. It is important 
to say that L-arginine as monotherapy was not effective, and 
perhaps harmful, in patients with intermittent claudication and 
peripheral artery disease.40
BH4 has shown efficacy in the treatment of erectile 
  dysfunction. Sommer et al found that BH4 administration led 
to a significant increase in duration of penile rigidity, making 
BH4 suitable as a treatment for erectile dysfunction.41
Oral administration of BH4 slows the progression of 
atherosclerosis and reduces the expression of NADPH 
oxidase and inflammatory factors in hypercholesterolemic 
apolipoprotein E-knockout mice.42
Other pharmacologic interventions 
to restore BH4 bioavailability  
and eNOS function
Nitrates
Nitrates (isosorbide, nitroglycerin) have been used as NO 
donors because they release NO.43 Unfortunately, chronic 
administration of nitroglycerin has been associated with 
  vascular production of superoxide and poor clinical 
benefits.12,44 A long-acting nitrate, pentaerythritol tetranitrate, 
may confer a better long-term cardiovascular prognosis.44
L-arginine
Several clinical studies have shown vasodilatation and 
enhanced NO production after administration of L-arginine. Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Drexler et al (cited by Tenenbaum et al45) showed that L-arginine 
enhanced the blood flow response to acetylcholine in patients 
with coronary artery disease but not in controls. Since then, 
there have been many studies with L-arginine in healthy 
human subjects and in patients with various cardiovascular 
conditions.45
In contrast, there have been several relatively small   clinical 
studies with experimental endpoints that failed to show benefi-
cial effects of L-arginine on vascular function. The evidence 
suggests that there may be subgroups of patients whose vascular 
function is improved by L-arginine supplementation, and other 
subgroups of patients who do not respond to this intervention. 
Because patients on “optimized medical treatment” and those 
with advanced coronary stenoses showed less effect, and L- 
arginine was more   effective when early changes in vascular func-
tion were chosen as endpoints. It is possible that this amino acid 
may have a role as a nutraceutical agent (daily doses below 2 to 3 
g/day appear to be without beneficial effect) in the modification 
of functional impairment and in the prevention of vascular dis-
ease, but not as a therapy to reverse manifest atherosclerosis.45,46 
In animal models, long-term administration of L-arginine 
inhibits the formation of atherosclerotic plaques.44
Folic acid
Because folic acid participates in the BH4 recycling pathway, 
several studies have been performed to investigate its use 
for the treatment of cardiovascular disease. Some results 
had shown that this agent may restore endothelial function 
in diabetic patients, as well as in hypercholesterolemic sub-
jects, and that it reduces atherosclerotic plaques in mice.44,46 
Unfortunately, those results have not been confirmed by 
recent clinical trials.47
Ascorbate
Ascorbate increases BH4 in endothelial cells via preven-
tion of oxidation of this biopterin, without an effect on its 
synthesis, and may explain the effect of ascorbate on blood 
pressure in hypertensive patients.33
Sepiapterin
Because sepiapterin is a precursor in the alternative BH4 
synthesis pathway, it has been proposed as a therapeutic 
approach for endothelial dysfunction.12 Indeed, acute   studies 
have shown that administration of sepiapterin restores 
endothelial function.44 However, because sepiapterin com-
petes with BH4 for the oxygenase domain in eNOS, higher 
doses of this precursor may increase superoxide production 
and decrease NO bioavailability.12,44 There are no studies 
that have evaluated the long-term effects of sepiapterin in 
vascular disease. This agent did not increase BH4 levels, but 
decreased BH2 concentrations,44 and a recent study shows 
that the BH4/BH2 ratio may be even more important than 
absolute BH4 levels for eNOS functioning.49
Statins
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors) are used in the management of dyslipidemia. 
These drugs have cholesterol-independent effects, may 
upregulate NO expression, and there is evidence that statins 
modulate atherogenesis, plaque rupture, and thrombosis.50
Hattori et al found that statins elevate GTP-CH mRNA. 
Because GTP-CH is the rate-limiting step in the synthesis 
of BH4, statins elevate levels of this biopterin in vascular 
endothelial cells, and they also enhance eNOS expression 
and increase the ratio of BH4/BH2.51
Because statins enhance BH4 synthesis, increase NO 
production, and prevent relative shortages of BH4, they 
also inhibit vascular NADPH oxidase and reduce oxidative 
stress,44 thereby normalizing endothelial function. In humans, 
statins not only reduce cardiovascular morbidity and mortal-
ity, but also reduce progression of coronary atherosclerosis 
in patients with coronary heart disease.52
Antagonism of the renin-angiotensin-
aldosterone system
Angiotensin II activates NADPH oxidase via AT1 receptor 
activation in vascular cells. However, NADPH oxidase is 
probably not the only source of ROS stimulated by angio-
tensin II. As we have reviewed, one consequence of increased 
superoxide production in response to angiotensin II is inacti-
vation of NO and resulting endothelial dysfunction, which is 
one of the earliest steps in the atherosclerotic process.52
Several studies have shown that inhibition of AT1   receptor 
activation by AT1 receptor antagonists or angiotensin-
  converting enzyme (ACE) inhibitors normalizes oxidative 
stress and improves endothelial dysfunction, and ACE 
i  nhibitors are known to retard the progression of atheroscle-
rosis and heart failure.53 Both AT1 receptor antagonists and 
ACE inhibitors provide an equivalent beneficial effect on 
risk of death and cardiovascular events.54
Like angiotensin II, aldosterone may also promote 
endothelial dysfunction and vascular disease. Imanishi et al 
found that eplerenone, an aldosterone antagonist, alone or 
combined with enalapril, reduces NADPH activity, and 
elevates both BH4 levels and NO bioavailability in endothe-
lial cells of hyperlipidemic rabbits.55Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Aliskiren, a direct renin inhibitor, as monotherapy or in 
combination with an AT1 receptor antagonist, also decreases 
NADPH oxidase activity, increases BH4 levels, and enhances 
NO bioavailability. Aliskiren also has an antiatherosclerotic 
effect.56
Conclusion
BH4 availability is a critical determinant of eNOS regula-
tion in atherosclerosis and is a rational therapeutic target to 
restore NO-mediated endothelial function and reduce disease 
progression in high-risk patients.
Strategies aimed at increasing BH4 biosynthesis or levels, 
reducing BH4 oxidation, or enhancing BH4 regeneration 
seem to be useful and safe therapeutic options for the preven-
tion of macrovascular complications in patients at high risk 
for cardiovascular complications, in particular patients with 
type 2 diabetes and/or hypertension.
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